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Background/Objective: Fibromyalgia syndrome (FMS) is a chronic, generalized pain condition character-
ized with widespread soft-tissue pain, fatigue, sleep disturbances, and tender points on physical ex-
amination. Although, there are numerous articles about the frequency of FMS in dermatologic diseases
such as psoriasis and chronic urticaria, few studies have been reported concerning skin ﬁndings in FMS.
Our objective was to evaluate the skin ﬁndings and skin-related symptoms in FMS patients and deter-
mine the quality of life in FMS patients with dermatologic diseases.
Methods: A total 105 female patients ages between 18 years and 65 years and diagnosed with FMS were
included in the study. A total of 105 healthy volunteers were age and sex matched in the control group.
Results: Skin related symptoms such as pruritus, burning, tingling, and increased sweating were more
common in FMS patients than in the control group. Xerosis, dermographism, lichen simplex chronicus,
neurotic excoriations, tinea pedis, and seborrheic dermatitis were more frequent in FMS patients and the
differences were statistically signiﬁcant. Presence of dermatologic disease or skin-related symptoms in
FMS patients did not affect the quality life of the FMS patients.
Conclusion: Genetic and pathophysiological studies to clarify the relationship between FMS and
dermatologic disorders will provide more information on the association and common treatment of
these disorders.
Copyright © 2016, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Fibromyalgia syndrome (FMS) is a chronic pain syndrome charac-
terized by widespread pain, fatigue, sleep and cognitive function
disorders.1,2
The disorder affects 2% of the population and is seven times
more common in females.3 A study from our country has reported
the FMS incidence in women aged 20e65 years as 3.6%.4y have no ﬁnancial or non-
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al Association. Published by ElseviThe etiopathogenesis is not clear but abnormalities in the cen-
tral pain mechanisms are thought to play a central role.2 The role of
peripheral nerves and neurogenic inﬂammation in FMS patho-
genesis has also attracted interest recently.5,6 FMS can also
accompany many disorders with a common pathogenetic mecha-
nism such as irritable bowel syndrome, chronic fatigue syndrome,
anxiety, and depression.7 Pathologic examination of FMS patients'
skin has revealed various changes such as oxidative stress and
increased numbers of cytokines and mast cells.8e10
Although there are studies that have investigated the FMS
incidence in dermatologic disorders such as psoriasis,11 chronic
urticarial,12e15 and Behçet's disease,16,17 there are only a few studies
on skin ﬁndings in FMS patients.18,19 The aim of our study was to
determine the possible accompanying skin ﬁndings in FMS pa-
tients, the incidence of cutaneous symptoms, and the quality of life
in FMS patients with dermatological disease.er Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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The study included a total of 105 female patients aged 18e65 years
who had been diagnosed with FMS by a Physical Therapy and
Rehabilitation specialist using the 2010 American College of
Rheumatology (ACR) FMS diagnostic criteria at the Physical Ther-
apy and Rehabilitation Department of our hospital. The new diag-
nostic criteria speciﬁed by the ACR in 2010 do not include tender
points examination, require exclusion of other causes of pain,
include symptoms other than pain, and evaluate the symptom
severity.20 The control group consisted of 105 age-matched female
patients with no systemic and rheumatoid disorder who had pre-
sented to the Ophthalmology Department of our hospital. Patients
with congestive heart failure, pulmonary failure, coronary heart
disease, neurological disorder, inﬂammatory rheumatologic dis-
ease, hypothyroidism, hyperparathyroidism, diabetes mellitus,
those who had started psychotropic or antihistaminic treatment
within the past month, and pregnant or breastfeeding patients
were excluded.
We obtained Erciyes University Ethics Committee (Kayseri/
Turkey) approval and written patient consent stating that they had
been informed about the study. The sociodemographic features,
cutaneous symptoms such as pruritus, burning, increased sweating,
numbing and tingling; personal history, and the family history of
FMS were queried. A detailed dermatologic examination was per-
formed by a dermatologist. The quality of life scale short form-36
(SF-36) was administered to the FMS patients.
SPSS version 22.0 package software (SPSS Inc., Chicago, IL, USA)
was used to analyze the data. We used the Kolmogorov Smirnov
test to evaluate the distribution of the variables. The Man-
neWhitney U test and the independent samples t test were used
for the analysis of quantitative data. The Chi-square test was used
for qualitative data and the Fischer's test was used when the Chi-
square test conditions were not met. A p value < 0.05 was
considered statistically signiﬁcant.Table 2 Comparison of cutaneous symptoms between FMS and control groups.a
FMS group Control group p
Cutaneous symptom 97 (92.4) 45 (42.9) <0.001
Pruritus 73 (69.5) 26 (24.8) <0.001
Burning 52 (49.5) 6 (5.7) <0.001
Hyperhidrosis 71 (67.6) 35 (33.3) <0.001
Others 36 (34.3) 0 (0) <0.001
Data are presented as n (%).Results
The mean age was 45.5 ± 8.7 years in the study group and
46.6 ± 9.7 years in the control group. There was no signiﬁcant
difference between the patient and control groups regarding age,
occupation, marital status, accompanying disorder, smoking, and
alcohol use. Stress (p ¼ 0.019), accompanying psychiatric disorder
(p¼ 0.009), and family history of FMS (p < 0.001) were signiﬁcantly
more common in the patient group (Table 1).Table 1 Demographic and clinical data of FMS patients and the control group.a
Age (y)
Occupation Working
House-wife
Marital status Single
Married
Family history of FMS
Stress
Smoking
Alcohol usage
Accompanying disorderb
Accompanying psychiatric disorderc Present
Absent
Data are presented as n (%) or mean ± standard deviation/median.
a Independent samples t test/Chi-square test
b Accompanying disorders were asthma, hypertension, anemia, hepatosteatosis, coron
cyst hydatid
c Accompanying psychiatric disorders were depression, panic attack, and panic disordThe percentage of at least one cutaneous symptomwas 92.4% in
FMS patients and 42.9% in the control group (p< 0.001). The rates of
other cutaneous symptoms such as pruritus at 69.5% (p < 0.001),
burning at 49.5% (p < 0.001), hyperhidrosis at 67.6% (p < 0.001), and
numbness and tingling at 34.3% were more common in the FMS
group than in the control group (p < 0.001; Table 2).
At least one dermatologic disorder was found in 78.1% of FMS
patients and in 46.7% of the control group. This difference was
statistically signiﬁcant (p < 0.001). The most common dermatologic
disorders in the FMS patients were xerosis (44.7%), lichen simplex
chronicus (15.2%), acne (10.4%), contact dermatitis (8.5%), neurotic
excoriation (6.6%), tinea pedis (6.6%), melasma (4.7%), and sebor-
rheic dermatitis (3.8%). Dermographismwas present in 30.5% of the
FMS patients and 8% of the control group (p < 0.001; Table 3).
Comparison of common disorders between the two groups
showed that xerosis (p ¼ 0.002), lichen simplex chronicus
(p¼ 0.011), neurotic excoriation (p¼ 0.031), tinea pedis (p¼ 0.007),
and seborrheic dermatitis (p ¼ 0.043) were more common in the
FMS group than the control group (Table 3).
We found that the presence of a dermatologic disorder or
cutaneous symptoms in FMS patients did not create a signiﬁcant
difference in the SF-36 physical function, physical role, pain, gen-
eral health, vitality, social function, emotional role, and mental
health scores.
Discussion
FMS is frequently accompanied by some medical, organic, and
psychiatric disorders and this concurrence has been named the
‘‘central sensitization syndrome’’.7 Some disorders that can
accompany FMS are obsessive-compulsive disorder, major
depression, dysthymia, panic disorder, generalized anxiety disor-
der, irritable bowel syndrome, migraine, and temporomandibular
joint disorders.21e24 We found a statistically signiﬁcantly higher
percentage of stress and accompanying psychiatric disorder in FMSFMS group Control group p
45.5 ± 8.7/45.0 46.6 ± 9.7/48.0 0.381
14 (13.3) 13 (12.4) 0.837
91 (86.7) 92 (87.6)
5 (4.8) 9 (8.6) 0.268
100 (95.2) 96 (91.4)
25 (23.8) 0 (0) <0.001
25 (23.8) 12 (11.4) 0.019
22 (21.0) 21 (20.0) 0.864
1 (1.0) 1 (1.0) 1.000
74 (70.5) 65 (61.9) 0.189
18 (17) 6 (6) 0.009
87 (83) 99 (94)
ary artery disease, heart valve disease, gastroesophageal reﬂux, nephrolithiasis, and
er.
a ManneWhitney U test.
Table 3 Comparison of dermatologic diseases between FMS and control groups.a
Dermatologic diseases FMS group Control group p
At least one dermatologic disease 82 (78.1) 49 (46.7) <0.001
Xerosis 47 (45) 26 (25) 0.002
Lichen simplex chronicus 16 (15) 5 (5) 0.011
Acne 11 (10) 6 (6) 0.206
Contact dermatitis 9 (9) 5 (5) 0.268
Neurotic excoriation 7 (7) 1 (1) 0.031
Tinea pedis 7 (7) 0 (0) 0.007
Melasma 5 (5) 1 (1) 0.098
Seborrheic dermatitis 4 (4) 0 (0) 0.043
Onychomycosis 4 (4) 1 (1) 0.174
Acrochordon 4 (4) 1 (1) 0.174
Urticaria 3 (3) 1 (1) 0.313
Rosacea 2 (2) 0 (0) 0.498
Verruca vulgaris 2 (2) 0 (0) 0.498
Brachioradial pruritus 1 (1) 0 (0) 1
Telogen efﬂuvium 1 (1) 0 (0) 1
Vitiligo 1 (1) 2 (2) 1
Onychophagia 1 (1) 0 (0) 1
Psoriasis 0 (0) 2 (2) 0.498
Data are presented as n (%).
a Chi-square test (Fischer's exact test).
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pathogenetic mechanisms such as neurochemical dysfunction,
serotonergic system hypofunction, and changes in hypothalamic-
pituitary-adrenal axis activity.24 The presence of stress and
accompanying disorders in our study could be an indicator of these
common pathogenetic mechanisms.
We found at least one cutaneous symptom such as pruritus,
increased sweating, numbness, and tingling in 92.4% of the FMS
patients in our study. Pathologic investigations of skin from FMS
patients in other studies have revealed changes such as increased
mast cells, mitochondrial dysfunction, coenzyme Q10 deﬁciency,
increased oxidative stress, increased expression of d and k opiate
receptors, increased interleukin (IL)-1b, IL-6, and tumor necrosis
factor-a, microcirculation abnormalities at tender points, vaso-
constriction, hypoxia and hypothermia, intradermal immunoglob-
ulin G deposits, and increased Type 3 collagen
reactivity.5,6,8e10,21,25,26 Mitochondrial dysfunction, increased
oxidative stress, and inﬂammation interdependently cause pe-
ripheral nerve damage and this is associated with the pain and
allodynia seen in FMS.26 Evaluation of the serum cytokine levels of
the patients has revealed increased IL-6, IL-8, and IL-1 receptor
antagonist and decreased T helper 2 cytokines.27e29
There is a complicated relationship between pain and pruritus.
We found pruritus as a symptom in 69.5% of the FMS patients in our
study. There are various similar mechanisms to explain the rela-
tionship between chronic pain and chronic pruritus such as pe-
ripheral and central sensitization, loss of inhibition in the spinal
cord, and neuroimmune and neuroglial interactions. In the physi-
ological conditions, itch and pain are encoded by labeled lines. But
in pathological conditions, the crosstalk of the pain and itch labeled
lines are disrupted. Pruritus and pain have both an antagonistic
relationship and similar sensitization processes.30,31 The high rate
of pruritus in our study may support the presence of this common
mechanism and common pathways.
Laniosz et al19 retrospectively evaluated 845 FMS patients in
their study on cutaneous symptoms and dermatologic disorders in
FMS patients. They found hyperhidrosis (32%), skin and mucosal
burning sensation (3.4%), various unusual cutaneous sensations
(1.7%), pruritus of unknown origin (3.3%), neurotic excoriation,
prurigo nodularis, lichen simplex chronicus (1.9%), and eczema
other than lichen simplex chronicus (9.1%). They stated that FMS-
related cutaneous problems can be present in FMS patients butthere was no markedly increased dermatologic diagnosis other
than a subjective increase in sweating.19
When accompanied dermatologic disorders are considered,
psychocutaneous diseases concept should not be ignored. Psychi-
atric and dermatologic disorders are closely related and are eval-
uated within the dermatology practice as psychocutaneous
disorders. The skin and brain originate from the ectoderm and are
affected by the same hormones and neurotransmitters. The neu-
ropeptides secreted from skin cells regulate the local neuroimmune
reactions in the skin as a response to the stress. Neurogenic
inﬂammation develops as a result of associated events and inter-
cellular interactions.24,32 Dogramacı and Yalcinkaya18 found the
incidence of xerosis and neurotic excoriation in FMS patients to be
signiﬁcantly higher than in the control group and concluded that
some stress-induced dermatologic problems could be seen
commonly in FMS patients. We also found incidences of 15.2% and
6.6%, respectively, for lichen simplex chronicus and neurotic exco-
riation, both psychocutaneous disorders. Any stressor can trigger
skin ﬁndings while also causing FMS. Another possibility is that this
relationship may not just be due to stress and that a certain type of
personality predisposed to FMS, lichen simplex chronicus or
neurotic excoriation may provide a suitable background for all
three disorders. However, this is only speculation for now as there
is no study supporting it.
In our study, we found that seborrheic dermatitis was more
common in the FMS group. Also we found a higher percentage of
stress in FMS patients. Stress is a well-known trigger of seborrheic
dermatitis. So the higher percentage of seborrheic dermatitis in
FMS patients can be explained by stress.
The third most common disorder in FMS patients was acne with
an incidence of 10.4% while the control group had an incidence of
6%. Although, the number of patients with acne in the test group
was more than in the control, the statistical difference between the
two groups was not signiﬁcant. Therefore, it may not indicate a
meaningful coexistence of the two disorders, acne and FMS. By
contrast, stress induces the hypothalamic-pituitary-adrenal axis
and substance P, which also plays a role in FMS pathogenesis and is
secreted from peripheral nerves, has recently been shown to
stimulate sebaceous gland proliferation and increase lipid synthesis
in the sebaceous cells.24 A stress-related indirect relationship be-
tween FMS and acne is likely, but this needs to be clariﬁed with
other studies.
There are several studies on the link between allergic disorders
and FMS in current literature. Tuncer et al33 found higher rates of
allergic disorders such as allergic rhinitis, atopic dermatitis,
asthma, allergic conjunctivitis, and eruptions related to drugs and
food in FMS patients. We found no increase in allergic disorders in
FMS patients in our study. The role of mast cells in FMS patho-
genesis is still not clear although increased numbers of mast cells
have been shown in FMS patients and the concurrence of chronic
urticaria and FMS has been reported.6,8,12e15
FMS has been reported at rates of 9.7%,15 23%,13 26%,12 and
70.6%14 in chronic urticaria patients. It has been speculated that the
neuropeptides secreted from the dysfunctional nerve endings
could cause vasodilation, plasma extravasation, and mast cell
degranulation in the dermal vessels. It is suggested that the reason
for the high FMS rate in chronic urticaria patients in these studies
could be related to neurogenic inﬂammation and autoimmunity.
The urticaria incidencewas 3% in FMS patients and 1% in the control
group while dermographism was positive at a rate of 30.5% in FMS
patients and 8% in the control group. The low incidence of chronic
urticaria in FMS patients despite the high rate of dermographism
suggests that there is an increase in the number of mast cells but
this is not reﬂected in the clinical ﬁndings. A study by Ang et al34 on
the effect of the mast cell stabilizer ketotifen on FMS symptoms has
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ketotifen (4 mg/d). We believe further clinicopathological studies
are needed to clarify the relationship between FMS and urticaria or
allergic disorders.
The FMS syndrome is known to cause functional disability and
have a negative effect on the patient's quality of life.35e37 Salafﬁ
et al37 found that the SF-36 physical component is related to
widespread pain, educational level, and body mass index while the
mental component is associated with widespread pain, sleep ab-
normalities, fatigue, age, and low educational level in FMS patients.
While we expected to ﬁnd that the presence of a dermatologic
disorder and cutaneous symptoms in FMS patients would create a
signiﬁcant change in the SF-36 scores, in the current study it did
not. This result as similar to the ﬁndings of a study carried out by
Dogramacı and Yalcinkaya.18 These results indicate that widespread
and chronic pain, sleep abnormalities, and chronic fatigue affect the
quality of life in FMS patients more than the accompanying
dermatologic problems.
In conclusion, some dermatologic problems such as xerosis, der-
mographism, lichen simplex chronicus, and neurotic excoriation are
seen frequently in FMS patients. The higher incidence of some
dermatologic disorders and cutaneous symptoms in FMS patients
may be due to the common genetic basis and pathophysiological
mechanisms insteadofbeinga coincidence.We think thatgenetic and
pathophysiological studies to clarify the relationship between FMS
and dermatologic disorders will provide more information on the
association and common treatment of these disorders. We also
believeFMSneedsamultidisciplinaryapproachwith theparticipation
of the dermatology and psychiatry departments as well as physical
therapy and rehabilitation for optimal management of FMS patients.
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